- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01914965
Apathy Cure Through Bupropion in Huntington's Disease (Action-HD)
September 8, 2014 updated by: Josef Priller, Charite University, Berlin, Germany
A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease
The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten (10) weeks of treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The safety and tolerability of Bupropion in HD.
The influence of Bupropion compared to placebo on the:
- change of apathy as quantified by the AES-C (clinician) or the AES-S (self),
- change of motor symptoms (UHDRS) and quantitative grip force motor assessment,
- change of cognitive symptoms (UHDRS and MMSE),
- change of psychiatric symptoms (UHDRS, HADS),
- change of activities of daily living (UHDRS),
- change of the NPI caregivers' distress score (NPI-D),
- change of ventral striatal and ventromedial prefrontal activation in response to a reward paradigm as quantified by fMRI.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bochum, Germany, 44791
- Neurologische Klinik der Ruhr-Universität Bochum
-
Ulm, Germany, 89081
- Universitätsklinikum Ulm, Klinik für Neurologie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Verified HD mutation carriers aged 25 to 75 years (inclusive) at first dosing
- Apathetic as diagnosed by SCIA-D criteria
- Stable concomitant medication (no change of medication during last six weeks prior to inclusion)
- Written informed consent by prospective study participant before conduct of any trial-related procedure. Participant must be able to make an informed decision of whether or not to participate in the study
- Patient has a caregiver (family member or friend), who is living in a close relationship with the patient and is willing to give written informed consent (caregiver) before performance of any trial-related procedure
Exclusion criteria:
- Pregnant or nursing women
- Active suicidality based on the answer "yes" in questions 4 and 5 of the Columbia-Suicide Severity Rating Scale (baseline version)
- Woman of childbearing potential, not using highly effective methods of contraception defined as methods with a Pearl Index < 1 such as oral, topical or injected contraception, IUD, contraceptive vaginal ring, or double barrier method such as diaphragm and condom with spermicide) or not surgically sterile (via hysterectomy, ovariectomy or bilateral tubal ligation) or not at least one year post-menopausal
- Male not using an acceptable barrier method for contraception and donating sperm from screening up to three months following treatment
- Presence or history of any medically not controllable disease (e.g. uncontrolled arterial hypertension or diabetes mellitus)
- Presence or history of seizures or diagnosed epilepsy or history of severe head trauma (contusion) or CNS tumor
- Clinical significant renal (calculated creatine clearance < 60 ml/min) or hepatic dysfunction
- Clinical significant depression defined by the NPI depression score (score ≥4 points) at screening
- Schizophreniform psychosis within the last 6 months prior to first dose
- History of anorexia or bulimia
- Severe cognitive disorders defined as a score < 18 in the Mini- Mental State Examination (MMSE) at screening
- Marked chorea (UHDRS 4) of face, BOL, trunk or extremities
- Treatment with neuroleptics other than tiapride, MAO-B inhibitors, amantadine, levodopa, D- or D,L-amphetamine or psychostimulants like methylphenidate, modafinil or atomoxetine within 1 month prior to first dose
- Known hypersensitivity reaction associated with bupropion, gelatine, lactose or magnesium stearate
- Clinically relevant abnormal findings in the ECG, the vitals, in the physical examination or laboratory values at screening that could interfere with the objectives of the study or the safety of the subject as judged by the investigator
- Acute disease state (e.g. nausea, vomiting, fever, diarrhoea, infection) within 7 days of first dose
- Definite or suspected personal history or family history of adverse reactions or hypersensitivity to the trial compounds (or to compounds with a similar structure)
- Presence of illicit drug and/or alcohol abuse
- Participation in another investigative drug trial within 2 months or donation of blood within 12 weeks prior to the first dose or during the trial
- Subjects who are unlikely to be compliant and attend scheduled clinic visits as required
- Placement in an institution due to governmental or judicial authorities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Bupropion
First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
|
Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
Other Names:
Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Other Names:
|
Placebo Comparator: Placebo
Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
|
Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
Other Names:
Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Apathy Evaluation Scale (AES-I)
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment.
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AES-C (clinician)
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-C, where C [clinician] is the trial investigator) in patients with HD after ten weeks of treatment.
|
10 weeks
|
AES-S (self)
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-S, where S [self] is the patient) in patients with HD after ten weeks of treatment.
|
10 weeks
|
Motor symptoms (UHDRS)
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on the UHDRS motor score in patients with HD after ten weeks of treatment.
|
10 weeks
|
Quantitative grip force motor assessment
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on motor scores in patients with HD after ten weeks of treatment.
|
10 weeks
|
Cognitive Symptoms
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on MMSE in patients with HD after ten weeks of treatment.
|
10 weeks
|
Psychiatric symptoms
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on UHDRS behavioural assessment in patients with HD after ten weeks of treatment.
|
10 weeks
|
Activities of daily living
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on UHDRS Functional Assessment in patients with HD after ten weeks of treatment.
|
10 weeks
|
Caregiver's distress
Time Frame: 10 weeks
|
The influence of Bupropion compared to placebo on the NPI caregiver's distress score.
|
10 weeks
|
ventral striatal and ventromedial prefrontal activation
Time Frame: 10 weeks
|
Change of ventral striatal and ventromedial prefrontal activation in response to a reward paradigm as quantified by fMRI.
|
10 weeks
|
Adverse events
Time Frame: 10 weeks
|
The safety and tolerability of Bupropion will be compared with placebo in patients with HD after ten weeks of treatment.
|
10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Josef Priller, MD, Charite University, Berlin, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
July 31, 2013
First Submitted That Met QC Criteria
July 31, 2013
First Posted (Estimate)
August 2, 2013
Study Record Updates
Last Update Posted (Estimate)
September 9, 2014
Last Update Submitted That Met QC Criteria
September 8, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Dopamine Uptake Inhibitors
- Bupropion
Other Study ID Numbers
- HDSY001
- 2009-013698-16 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington's Disease
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
SOM Innovation Biotech SACompleted
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedHuntington Disease | Alzheimer's DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
Clinical Trials on Bupropion
-
Orexigen Therapeutics, IncCompleted
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingBe Diagnosed With Cancer and Have Completed Systemic TherapyUnited States
-
Altschuler, Eric, M.D.GlaxoSmithKlineCompleted
-
Alembic Pharmaceuticals Ltd.CompletedBioequivalenceCanada
-
Mayo ClinicNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Completed
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedSmoking Cessation | Genetic PredispositionBrazil
-
NRG OncologyNational Cancer Institute (NCI)CompletedBreast Carcinoma | Cervical Carcinoma | Vaginal Carcinoma | Ovarian Carcinoma | Uterine Corpus Cancer | Vulvar Carcinoma | PostmenopausalUnited States
-
University of Wisconsin, MadisonNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)Completed
-
Vastra Gotaland RegionRecruitingAlcohol Dependence | Alcoholism | Alcohol Use DisorderSweden